Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
- PMID: 17611560
- DOI: 10.1038/sj.leu.2404833
Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
Abstract
Mesenchymal stem cells (MSC) possess anti-inflammatory properties and participate in tissue repair. We used MSC to heal therapy-induced tissue toxicity. Ten consecutive patients, treated with MSC due to tissue toxicity following allogeneic hematopoietic stem cell transplantation, (ASCT) were included. Their median age was 48 (13-64) years. Seven had hemorrhagic cystitis grades 2-5, two had pneumomediastinum and one had perforated colon and peritonitis. MSC donors were mainly third-party, HLA-mismatched (n=11), HLA-haploidentical (n=3) and, in two cases, the HLA-identical ASCT sibling donors. MSC were given intravenously, the median cell dose was 1.0 (range 0.7-2)x10(6)/kg. In five patients, the severe hemorrhagic cystitis cleared after MSC infusion. Gross hematuria disappeared after median 3 (1-14) days. Two patients had reduced transfusion requirements after MSC infusion, but died of multiorgan failure. In one of them, MSC donor DNA was demonstrated in the urinary bladder. In two patients, pneumomediastinum disappeared after MSC infusions. A patient with steroid-resistant graft-versus-host disease of the gut experienced perforated diverticulitis and peritonitis that was reversed twice by MSC. MSC is a novel treatment for therapy-induced tissue toxicity.
Comment in
-
Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia.Leukemia. 2008 Jun;22(6):1256-7. doi: 10.1038/sj.leu.2405013. Epub 2007 Nov 1. Leukemia. 2008. PMID: 17972946 No abstract available.
Similar articles
-
Mesenchymal stromal cells as an adjuvant treatment for severe late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.Acta Haematol. 2015;133(1):72-7. doi: 10.1159/000362530. Epub 2014 Aug 16. Acta Haematol. 2015. PMID: 25139500
-
Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages.Best Pract Res Clin Haematol. 2011 Mar;24(1):65-72. doi: 10.1016/j.beha.2011.01.003. Epub 2011 Feb 25. Best Pract Res Clin Haematol. 2011. PMID: 21396594 Review.
-
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.Transplantation. 2006 May 27;81(10):1390-7. doi: 10.1097/01.tp.0000214462.63943.14. Transplantation. 2006. PMID: 16732175 Clinical Trial.
-
[The outcome and safety of mesenchymal stem cells from bone marrow of a third party donor in treatment of secondary poor graft function following allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):98-102. Zhonghua Xue Ye Xue Za Zhi. 2012. PMID: 22730656 Chinese.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Stem cells in sepsis and acute lung injury.Am J Med Sci. 2011 Apr;341(4):325-32. doi: 10.1097/MAJ.0b013e3181f30dee. Am J Med Sci. 2011. PMID: 20890174 Free PMC article. Review.
-
Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects.Tissue Eng Part A. 2010 Dec;16(12):3555-68. doi: 10.1089/ten.TEA.2010.0471. Epub 2010 Oct 12. Tissue Eng Part A. 2010. PMID: 20715884 Free PMC article.
-
[Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation].Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):488-493. doi: 10.3760/cma.j.issn.0253-2727.2022.06.008. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35968592 Free PMC article. Chinese.
-
Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses.PLoS One. 2011;6(7):e21703. doi: 10.1371/journal.pone.0021703. Epub 2011 Jul 1. PLoS One. 2011. PMID: 21747949 Free PMC article.
-
Establishment of a mesenchymal stem cell bank.Stem Cells Int. 2011;2011:905621. doi: 10.4061/2011/905621. Epub 2011 Aug 4. Stem Cells Int. 2011. PMID: 21826152 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials